Is Symbiox Investme overvalued or undervalued?

As of 7 August 2025, the valuation grade for Symbiox Investme has moved from fair to attractive, indicating a positive shift in its perceived value. The company is currently considered undervalued based on its financial metrics, which include a PE ratio of 7.76, a price to book value of 0.24, and a PEG ratio of 0.05. These figures suggest that the stock is trading at a significant discount compared to its earnings growth potential.
In comparison to its peers, Symbiox Investme stands out with a much lower PE ratio than Life Insurance, which has a PE of 11.59, and Bajaj Finance, which is at 31.34. Additionally, the company's EV to EBITDA ratio of -3.35 further emphasizes its undervaluation relative to the industry. Despite recent underperformance compared to the Sensex, with a year-to-date return of -54.24% against the Sensex's 3.18%, the attractive valuation metrics suggest potential for recovery and growth.